Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights
  • Choose License Type

Global Alagille Syndrome Treatment Market, by Drug (Ursodeoxycholic Acid, Cholestyramine, Rifampicin, Late Stage Pipeline Drugs, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 69.6 million in 2020 and is expected to exhibit a CAGR of 45.2% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Alagille Syndrome Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

In Alagille syndrome, majority of patients suffer from severe liver damage, heart conditions, severe skin itch, and others, and the treatment might be delayed due to the pandemic. During the COVID-19 pandemic, the treatment or liver transplant for severe liver damage patients is postponed or even cancelled due to the unavailability of antibiotics, laxatives, and other medications, and irregular supply and transportation of drugs. Moreover, according to a study published in Antimicrobial Agents and Chemotherapy (journal), the monthly use of antibiotic therapy for March 2020 through June 2020 fell by 151.5% per month, when compared to January 2018 through February 2020, a 6.5% monthly reduction in use of antibiotics.

The increasing number of research and development, clinical trials, and rising funding gained by key players for research and development of novel drugs for Alagille syndrome are the major factors, which are expected to drive growth of the Alagille syndrome treatment market during the forecast period.

Rising clinical trials for development of advanced Alagille syndrome treatments drugs is expected to propel the Alagille syndrome treatment market growth over the forecast period. For instance, on December 17, 2020, Albireo Pharma, Inc., a clinical-stage rare liver disease company developing novel bile acid modulators, announced the initiation of its global Phase 3 pivotal trial, ASSERT, Alagille Syndrome looking at safety and efficacy in a randomized controlled trial, which will evaluate odevixibat in patients with Alagille syndrome. Odevixibat is a potent, once-daily, non-systemic ileal bile acid transport inhibitor (IBATi) being investigated for the treatment of rare pediatric cholestatic liver diseases, including progressive familial intrahepatic cholestasis (PFIC), biliary atresia, and Alagille syndrome (ALGS).

Rising funding for the development of novel therapies for the treatment of Alagille syndrome is expected to contribute significantly to the Alagille syndrome treatment market growth. For instance, in September 2018, Mirum Pharmaceuticals announced that it secured US$ 120 million in Series A financing to support development of its lead drug candidate maralixibat for rare cholestatic liver disease. The financing was led by New Enterprise Associates (NEA) with participation from Deerfield Management, Frazier Healthcare Partners, Novo Holdings A/S, Pappas Capital, RiverVest Venture Partners, and Rock Springs Capital.

Browse 26 Market Data Tables and 29 Figures spread through 156 Pages and in-depth TOC on Alagille Syndrome Treatment Market, by Drug (Ursodeoxycholic Acid, Cholestyramine, Rifampicin, Late Stage Pipeline Drugs, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2027"

To know the latest trends and insights related to Alagille Syndrome Treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/alagille-syndrome-treatment-market-4398

Rising awareness about the Alagille syndrome is expected to support growth of the Alagille syndrome treatment market over the forecast period. For instance, in January 2020, Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, commemorated the first International Alagille Awareness Day on January 24, 2020. Furthermore, increasing prevalence of Alagille syndrome is expected to boost the Alagille syndrome treatment market growth in the near future. For instance, according to the National Organization for Rare Disorders (NORD), the incidence of Alagille syndrome has been estimated to be around 1 in 30,000-45,000 individuals in the global population. Alagille syndrome affects males and females equally.

Key Takeaways of the Alagille Syndrome Treatment Market:

  • The Alagille syndrome treatment market is expected to exhibit a CAGR of 45.2% during the forecast period (2020-2027), owing to increasing number research and development activities for novel drug development for treatment of Alagille Syndrome by key players.
  • Among drug, Ursodeoxycholic acid segment is expected to hold a major revenue share in 2027, as demand of ursodeoxycholic acid is high, as it is mostly used for children suffering from the alagille syndrome, which is expected to drive the segment growth during the forecast period. Ursodeoxycholic acid promotes excretion of more hydrophilic bile and has a membrane-stabilizing effect, which reduces disruption of cholesterol-rich membranes. Ursodeoxycholic acid is an artificial bile salt widely used as a first-line therapy to treat symptoms associated with alagille syndrome such as pruritus (itching) and xanthomas (skin lesions containing cholesterol & fats).
  • Major players operating in the Alagille syndrome treatment market include Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals Limited, Par Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Sanofi S.A., Novartis International AG, Akorn, Inc., Albireo Pharma, Inc., and Mirum Pharmaceuticals.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.